More recently, the addition of nivolumab (anti-PD-1) or pembrolizumab (anti-PD-1) to neoadjuvant chemotherapy in high-risk, hormone-receptor-positive (HR+) breast cancer (BC) has been shown to improve pathological complete response (pCR) rates, although the data on survival benefits are immature at present [1,2]. This evidence concerns the gene NR4A1 and breast cancer.